Tadalafil: A Clinical Update
Abstract
Oral phosphodiesterase type-5 inhibitors are the contemporary choice for first-line treatment of erectile dysfunction in most men. Due to its efficacy, safety and ease-of-use, tadalafil is preferred by many men suffering from erectile dysfunction of varying severity and etiology. In this review, pharmacodynamic and updated clinical data from integrated analyses and postmarketing surveillance of tadalafil are reported, including efficacy results for specific patient subpopulations, treatment guidelines and compiled safety data including a review of nonarteritic anterior ischemic optic neuropathy and possible links to the use of phosphodiesterase-5 inhibitors.
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
- Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent
- Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review
- Molecular Docking of Silymarin as a Ligand for Aromatase Enzyme and HIV-1 Reverse Transcriptase Using Molegro Virtual Docker
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.